Acción CINC CINCOR PHARMA, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas CinCor Pharma, Inc.

Acciones

CINC

US17240Y1091

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Acquisition of CinCor Pharma complete
AstraZeneca Completes $1.8 Billion Acquisition of CinCor Pharma to Boost Cardiorenal Portfolio
AstraZeneca closes CinCor buy; Enhertu wins Chinese approval
AstraZeneca : acquisition de CinCor finalisée
CinCor Pharma : Acquisition/Asset Disposal - Form 8-K
CINCOR PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Composite Index
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P Global BMI Index
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P TMI Index
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Biotechnology Index
Astrazeneca Finance And Holdings Inc. completed the acquisition of CinCor Pharma, Inc. from a group of shareholders.
CINCOR PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat
CinCor Pharma, Inc. Announces Completion of End-of-Phase 2 Meeting with U.S. Food and Drug Administration on Anticipated Phase 3 Program for Baxdrostat in Hypertension
CINCOR PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC
AstraZeneca Initiates Tender Offer For $2 Billion CinCor Takeover
ADRs End Higher; AstraZeneca, Barclays Trade Actively
Biotech IPO Window to Reopen in 2023 Following Muted Activity in 2022, Oppenheimer Says
AstraZeneca : ouverture de l'offre amicale sur CinCor
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción CINC
  4. Noticias CinCor Pharma, Inc.
  5. Otros idiomas